<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304770</url>
  </required_header>
  <id_info>
    <org_study_id>FDZJALA-201409</org_study_id>
    <nct_id>NCT02304770</nct_id>
  </id_info>
  <brief_title>Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia</brief_title>
  <official_title>A Pilot Study of Aminolaevulinic Acid (ALA) Photodynamic Therapy (PDT) in Patients With Cervical Persistent High Risk HPV Infection or Cervical Intraepithelial Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the effect of aminolaevulinic acid (ALA) photodynamic therapy (PDT) of
      cervical precancerous lesions in women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 months after treatments</time_frame>
    <description>Based on histology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clearance of high risk HPV</measure>
    <time_frame>3 months after treatments</time_frame>
    <description>proportion of patients with high risk HPV clearance</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Cervical Persistent High Risk HPV Infection</condition>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>cervical persistent high risk HPV infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aminolaevulinic acid photodynamic therapy for the treatment of patients with cervical persistent high risk HPV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIN 1 with high risk HPV infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 1 and high risk HPV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIN 2/3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 2/3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminolaevulinic acid photodynamic therapy</intervention_name>
    <description>Aminolaevulinic acid mediated photodynamic therapy</description>
    <arm_group_label>cervical persistent high risk HPV infection</arm_group_label>
    <arm_group_label>CIN 1 with high risk HPV infection</arm_group_label>
    <arm_group_label>CIN 2/3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premenopausal women, 25-50 years of age

          2. Meet one of the 3 following conditions:

             high-risk HPV-DNA persistently positive for at least 6 months, without CIN or higher
             grade lesions as verified by cervical biopsy within the last 3 months; CIN1 as
             verified by cervical biopsy within the last 3 months and high-risk HPV-DNA positive;
             CIN2/3 as verified by cervical biopsy within the last 3 months, with intense desire to
             retain the cervical structure or function

          3. Satisfactory colposcopy examination (visibility of entire transformation zone and
             entire lesion margin ) and endocervical curettage negative

          4. In good health condition as confirmed by past medical history, physical examination,
             electrocardiogram, laboratory tests and urinalysis on the screening and baseline
             evaluation within the last 4 weeks of the onset of the study

          5. Meet the following conditions: pregnancy test negative; no pregnancy plan during the
             trial;no sexuality or reliable contraceptive measures taken since last menstruation to
             the onset of the study, agreeing to adopt reliable contraceptive measures during the
             study

          6. Written informed consent signed

        Exclusion Criteria:

          1. Atypical glandular cells of undetermined significance (AGUS) or adenocarcinoma in situ
             (AIS) on cytology ,or malignant cells on cytology or histology, or other suspicion of
             either micro-invasive or invasive disease

          2. Invasive carcinoma possibility or positive endocervical curettage on colposcopy

          3. Severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological
             infection as per clinical examination

          4. Undiagnosed vaginal bleeding

          5. With allergic disease at present; known or suspected porphyria; known allergy to ALA
             or similar compounds

          6. Evidence or history of clinically significant cardiovascular, endocrine, neurologic,
             pulmonary, hematological, immunological, psychiatric, metabolic disease or other
             serious diseases

          7. Pregnancy or nursing

          8. Therapeutic drug or other therapeutic measures applied on cervix or rectum within the
             last 2 weeks of the onset of the study

          9. Participation in any clinical studies within the last 30 days

         10. Subjects that the investigators judged to be not suitable to participate the study
             besides above
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beihua Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youzhong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jining Tao, Master</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Obstetrics &amp; Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Hospital School of Medicine Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

